Janelidze, S;
Stomrud, E;
Palmqvist, S;
Zetterberg, H;
van Westen, D;
Jeromin, A;
Song, L;
... Hansson, O; + view all
(2016)
Plasma beta-amyloid in Alzheimer's disease and vascular disease.
Scientific Reports
, 6
(26801)
10.1038/srep26801.
![[thumbnail of Plasma β-amyloid in Alzheimer's disease and vascular disease.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Plasma β-amyloid in Alzheimer's disease and vascular disease.pdf - Published Version Download (0B) |
Abstract
Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer’s disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.
| Type: | Article |
|---|---|
| Title: | Plasma beta-amyloid in Alzheimer's disease and vascular disease |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1038/srep26801 |
| Publisher version: | http://doi.org/10.1038/srep26801 |
| Language: | English |
| Additional information: | Copyright © 2017 The Author(s). Al rights reserved. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Science & Technology, Multidisciplinary Sciences, Science & Technology - Other Topics, Cerebrospinal-fluid Biomarkers, Mild Cognitive Impairment, White-matter Lesions, A-beta, Apolipoprotein-e, Rating-scale, Risk, Dementia, Validation, Diagnosis |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1537461 |
Archive Staff Only
 |
View Item |
